Drug Profile

AT 702

Alternative Names: AT-702; scAAV9 U7 ACCA - Astellas Gene Therapies; scAAV9.U7.ACCA - Astellas Gene Therapies

Latest Information Update: 02 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Audentes Therapeutics
Developer Astellas Gene Therapies
Class Antisense oligonucleotides
Mechanism of Action Dystrophin expression stimulants; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Duchenne muscular dystrophy

Most Recent Events

01 Aug 2022 Discontinued - Phase-I/II for Duchenne muscular dystrophy (In children) in USA (IV) prior to August 2022 (NCT04240314)
01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
15 Jan 2020 Phase-I/II clinical trials in Duchenne muscular dystrophy (In children) in USA (IV) (NCT04240314)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com